非侵襲的出生前検査（NIPT）市場- 世界および地域別分析：方法別、検査別、プラットフォーム別、エンドユーザー別、用途別、地域別 - 分析と予測（2023年～2033年）

世界の非侵襲的出生前検査（NIPT）の市場規模は、2023年に33億5,040万米ドルとなりました。

同市場は、2033年には128億7,090万米ドルに達すると予測され、予測期間のCAGRは14.41%になるとみられています。世界のNIPT市場は、NIPTガイドラインの奨励、スクリーニング手技に対する支払者の償還、継続的な技術革新、地域間の商業的可能性、非侵襲的検査法に対する嗜好の高まりなどが主な要因となっています。

世界のNIPT市場は、既存企業と新興企業が市場シェアを争う激しい競争が特徴です。市場の予想される成長と変容は、課題と機会の両方をもたらし、今後数年間で観察すべきダイナミックな風景となります。

染色体異常の早期発見と予防に対する意識の高まり、非侵襲的手法の採用の増加、診断検査の消費者化など、ミクロとマクロの動向の合流が、市場の将来的な成長に向けた原動力となっています。染色体異常以外にも、研究から臨床検査への移行、より迅速な介入を可能にする早期妊娠検査、技術の進歩と保険適用範囲の拡大による手頃な価格の増加など、業界の技術的飛躍が予想されます。現在の限界とアンメットニーズに対処するための研究開発の増加は、今後の市場成長をさらに促進するとみられています。

当レポートでは、世界の非侵襲的出生前検査（NIPT）市場について調査し、市場の概要とともに、方法別、検査別、プラットフォーム別、エンドユーザー別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

• 動向：現在および将来の影響評価
• サプライチェーンの概要
• 研究開発レビュー
• 規制状況
• 償還シナリオ
• 市場力学の概要

第2章 用途

• 用途のセグメンテーション
• 用途の概要
• 世界の非侵襲的出生前検査市場（用途別）
• 世界の非侵襲的出生前検査市場（エンドユーザー別）

第3章 製品

• 製品セグメンテーション
• 製品概要
• 世界の非侵襲的出生前検査市場（検査別）
• 世界の非侵襲的出生前検査市場（方法別）
• 世界の非侵襲的出生前検査市場（プラットフォーム別）

第4章 地域

• 促進要因と抑制要因
• 地域別概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第5章 市場-競合ベンチマーキングと企業プロファイル

• 今後の見通し
• 競合情勢
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • BGI Genomics
  • CENTOGENE N.V.
  • Laboratory Corporation of America Holdings
  • MedGenome Inc.
  • Annoroad Gene Technology
  • Natera, Inc.
  • Yourgene Health
  • Eurofins Scientific SE
  • Next Biosciences

第6章 調査手法

List of Figures

• Figure 1: Global Non-Invasive Prenatal Testing Market (by Region), $Million, 2022, 2026, and 2033
• Figure 2: Prevalence of Genetic Disorders in Early Pregnancy, U.S., 2022
• Figure 3: Global Non-Invasive Prenatal Testing Market (by Application), $Million, 2022, 2026, and 2033
• Figure 4: Global Non-Invasive Prenatal Testing Market (by End User), $Million, 2022, 2026, and 2033
• Figure 5: Global Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022, 2026, and 2033
• Figure 6: Global Non-Invasive Prenatal Testing Market (by Method), $Million, 2022, 2026, and 2033
• Figure 7: Global Non-Invasive Prenatal Testing Market, Recent Developments, 2023
• Figure 8: Supply Chain of Global NIPT Market
• Figure 9: Global NIPT Market, Patent Analysis, (by Country), January 2020-December 2023
• Figure 10: Global NIPT Market, Patent Analysis, (by Year), January 2020-December 2023
• Figure 11: Reimbursement Scenario in Major Countries of the Global NIPT Market
• Figure 12: Impact Analysis of Market Navigating Factors, 2022-2033
• Figure 13: Births with Trisomies per 100,000 Live Births in Europe Region, 2000-2021
• Figure 14: Age of Mother at Childbirth over the Years
• Figure 15: Reimbursement Scenario in Major Countries
• Figure 16: Number of Tests Processed by Natera, Inc., 2018-2020
• Figure 17: Positives from Data of 75,000 NIPT Tests Showing False Positives
• Figure 18: Recent Developments in APAC by Key Companies
• Figure 19: North America Non-Invasive Prenatal Testing Market, Thousand Unit, 2023-2033
• Figure 20: North America Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 21: U.S. Non-Invasive Prenatal Testing Market, Thousand Unit, 2023-2033
• Figure 22: U.S. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 23: Canada Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 24: Canada Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 25: Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 26: Europe Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 27: France Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 28: France Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 29: Germany Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 30: Germany Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 31: U.K. Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 32: U.K. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 33: Spain Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 34: Spain Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 35: Italy Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 36: Italy Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 37: Rest-of-Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 38: Rest-of-Europe Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 39: Asia-Pacific Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 40: Asia-Pacific Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 41: China Non-Invasive Prenatal Testing Market, Thousand, 2023-2033
• Figure 42: China Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 43: India Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 44: India Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 45: Japan Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 46: Japan Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 47: Rest-of-Asia-Pacific Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 48: Rest-of-Asia-Pacific Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 49: Latin America Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 50: Latin America Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 51: Brazil Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 52: Brazil Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 53: Mexico Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 54: Mexico Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 55: Rest-of-Latin America Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 56: Rest-of-Latin America Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 57: Middle East and Africa Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
• Figure 58: Middle East and Africa Non-Invasive Prenatal Testing Market, $Million, 2023-2033
• Figure 59: U.A.E. Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 60: U.A.E. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 61: South Africa Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 62: South Africa Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 63: Rest-of-Middle East and Africa Non-Invasive Prenatal Testing Market, Thousand Units, 2022-2033
• Figure 64: Rest-of-Middle East and Africa Non-Invasive Prenatal Testing Market, $Million, 2022-2033
• Figure 65: Share of Strategic Initiatives
• Figure 66: Data Triangulation
• Figure 67: Top-Down and Bottom-Up
• Figure 68: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Global Non-Invasive Prenatal Testing Market, Opportunities
• Table 3: Market Share of Major Players
• Table 4: Key Companies' Partnerships and Alliances
• Table 5: NIPT Tests in the NIPT Market and their Corresponding Applications
• Table 6: Risk of Chromosomal Abnormality w.r.t Maternal Age
• Table 7: Global Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 8: Global Non-Invasive Prenatal Testing Market (by Application), Thousand Units, 2022-2033
• Table 9: Global Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 10: Global Non-Invasive Prenatal Testing Market (by End User), Thousand Units, 2022-2033
• Table 11: Global Non-Invasive Prenatal Testing Market, by Test, $Million
• Table 12: Global Non-Invasive Prenatal Testing Market, by Platform, $Million
• Table 13: Global Non-Invasive Prenatal Testing Market, by Platform, Thousand Unit
• Table 14: Global Non-Invasive Prenatal Testing Market, by Method, $Million
• Table 15: Global Non-Invasive Prenatal Testing Market, by Method, Thousand Unit
• Table 16: Global Non-Invasive Prenatal Testing Market (by Region), Thousands Units, 2022-2033
• Table 17: Global Non-Invasive Prenatal Testing Market (by Region), $Million, 2022-2033
• Table 18: North America Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 19: North America Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 20: North America Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 21: North America Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 22: U.S. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 23: U.S. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 24: U.S. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 25: U.S. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 26: Canada Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 27: Canada Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 28: Canada Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 29: Canada Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 30: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 31: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 32: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 33: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 34: France Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 35: France Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 36: France Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 37: France Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 38: Germany Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 39: Germany Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 40: Germany Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 41: Germany Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 42: U.K. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 43: U.K. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 44: U.K. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 45: U.K. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 46: Spain Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 47: Spain Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 48: Spain Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 49: Spain Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 50: Italy Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 51: Italy Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 52: Italy Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 53: Italy Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 54: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 55: Rest-of-Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 56: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 57: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 58: Asia-Pacific Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 59: Asia-Pacific Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 60: Asia-Pacific Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 61: Asia-Pacific Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 62: China Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 63: China Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 64: China Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 65: China Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 66: India Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 67: India Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 68: India Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 69: India Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 70: Japan Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 71: Japan Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 72: Japan Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 73: Japan Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 74: Rest-of-Asia-Pacific Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 75: Rest-of-Asia-Pacific Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 76: Rest-of-Asia-Pacific Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 77: Rest-of-Asia-Pacific Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 78: Latin America Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 79: Latin America Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 80: Latin America Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 81: Latin America Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 82: Brazil Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 83: Brazil Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 84: Brazil Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 85: Brazil Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 86: Mexico Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 87: Mexico Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 88: Mexico Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 89: Mexico Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 90: Rest-of-Latin America Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 91: Rest-of-Latin America Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 92: Rest-of-Latin America Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 93: Rest-of-Latin America Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 94: Middle East and Africa Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 95: Middle East and Africa Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 96: Middle East and Africa Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 97: Middle East and Africa Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 98: U.A.E. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 99: U.A.E. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 100: U.A.E. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 101: U.A.E. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 102: South Africa Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 103: South Africa Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 104: South Africa Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 105: South Africa Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 106: Rest-of-Middle East and Africa Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
• Table 107: Rest-of-Middle East and Africa Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
• Table 108: Rest-of-Middle East and Africa Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
• Table 109: Rest-of-Middle East and Africa Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
• Table 110: Market Share (2022)

Global Non-Invasive Prenatal Testing Market Overview

The global NIPT market was valued at $3,350.4 million in 2023 and is expected to reach $12,870.9 million by 2033, registering a CAGR of 14.41% during the forecast period 2023-2033. The global NIPT market is primarily driven by the increase in encouraging NIPT guidelines, payers reimbursing for screening procedures, continued technology innovation, commercial potential across geographies, and growing preferences for non-invasive testing methods.

Market Lifecycle Stage

The global NIPT market is characterized by intense competition, as established entities and emerging players compete for a share of the market. The anticipated growth and transformation of the market bring forth both challenges and opportunities, rendering it a dynamic landscape to observe in the upcoming years.

Industry Impact

The confluence of micro and macro trends such as increasing awareness for early chromosomal abnormality detection and prevention, rise in adoption of non-invasive methods, and consumerization of diagnostic tests are driving the market toward future growth. The industry is expected to witness technological leaps with offerings beyond chromosomal abnormalities moving from research to clinical testing, early pregnancy testing enabling faster intervention, and increased affordability due to technological advancements and wider insurance coverage. Increase in research and development to address the current limitations and unmet needs will further propel the market growth in future.

The industry's advancements in NIPT research and development continually address population health trends, disease prevalence, and treatment outcomes. As a result, the NIPT market's impact extends beyond technological integration for diagnosis, making it an integral component of global health strategies and broader ecosystem.

Market Segmentation:

Segmentation 1: by Application

• Trisomy Detection
• Microdeletion Detection
• Sex Chromosome Aneuploidy Detection
• Others

Trisomy Detection to Dominate the Global Non-Invasive Prenatal Testing Market (by Application)

The trisomy detection segment dominated the global NIPT market (by application) in FY2022.

The high specificity, efficiency, and safety of NIPT (over 99% for trisomy 21), increased accessibility, rising incidence of chromosomal abnormalities, and increasing maternal age are collectively driving the market growth.

Segmentation 2: by End User

• Hospitals
• Diagnostic Laboratories
• Others

Hospitals to Dominate the Global Non-Invasive Prenatal Testing Market (by End User)

Larger patient database due to existing maternity and prenatal care services, both public and private hospitals specialized medical staff, easier access to genetic counselors and other specialists for pre- and post-test consultations, and potential integrated workflow with diagnostic procedures like amniocentesis in case of positive NIPT results are driving the hospital segment growth.

Segmentation 3: by Platform

• NGS
• PCR
• Others

NGS to Dominate the Global Non-Invasive Prenatal Testing Market (by Platform)

The global NIPT market (by product) was dominated by the NGS segment in FY2022. NGS-based NIPT tests are more prevalent due to shift in its affordability, high throughput and accuracy, integration with other technologies enabling efficient data interpretation, and shorter turnaround times.

Segmentation 4: by Method

• cfDNA
• FCMB

cfDNA to Dominate the Global NIPT Market (by Method)

The global NIPT market (by product) was dominated by the cfDNA segment in FY2022. cfDNA analysis is being explored for additional applications like determining fetal sex, identifying single-gene disorders, and even assessing fetal health and development driving the growth.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The NIPT market in the Asia-Pacific region is witnessing significant growth of 15.43% in the forecast period, marked by increasing number of market players, and shifting healthcare landscape. In 2022, Asia-Pacific accounted for a share of 19.50% of the global NIPT market.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

High Incidence of Genetic Disorders: With the rising incidence of genetic diseases, early diagnostic intervention is a key factor leading to the growth of NIPT solutions worldwide.

Market Restraints:

Stringent Regulatory Guidelines and Ethical Hurdles: Numerous regulatory bodies worldwide express concerns that the widespread implementation of NIPT and the subsequent surge in prenatal testing adoption could lead to an increase in abortion rates.

Market Opportunities:

Leveraging the Opportunities Arising from the Growing Markets in Asia: The growing markets in Asia present a significant opportunity for the noninvasive prenatal testing (NIPT) sector, providing avenues for expansion and innovation. As healthcare awareness and infrastructure continue to improve across Asian countries, there is an increasing demand for advanced prenatal screening technologies. Leveraging these opportunities involves tailoring NIPT solutions to meet the diverse genetic profiles and cultural considerations in the region.

How can this report add value to an organization?

Workflow/Innovation Strategy: The NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the global NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
• The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2023 to 2033.
• The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of offerings to the NIPT market have been considered and profiled in the report.
• In the study, the primary respondent's verification has been considered to finalize the estimated market for the NIPT market.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Food and Drug Administration (FDA), PubMed, and National Center for Biotechnology Information (NCBI)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

NIPT refers to a method of examining fetal deoxyribonucleic acid (DNA) to determine the risk of genetic abnormalities in the developing fetus. The testing is usually done by taking a sample of blood from a pregnant woman and analyzing small fragments of DNA that are circulating in a pregnant woman's blood. The test helps in the screening of chromosomal abnormalities, specifically the trisomies that cause Down's, Edward's, and Patau's syndromes.

The global non-invasive prenatal testing market is in growth phase and rapidly expanding, creating opportunities for emerging players embracing targeted analysis without PCR or sequencing methods to enable broader adoption and challenge large players position in the market such as Natera, Illumina, LabCorp, Roche Molecular Systems/BioReference Laboratories, and BGI Genomics.

Some of the prominent companies in this market are:

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• PerkinElmer, Inc.
• Quest Diagnostics Incorporated
• Illumina, Inc.
• Myriad Genetics, Inc.
• BGI Genomics
• CENTOGENE N.V.
• Laboratory Corporation of America Holdings
• MedGenome Inc.
• Annoroad Gene Technology
• Natera, Inc.
• Yourgene Health
• Eurofins Scientific SE
• Next Biosciences

Companies that are not a part of the aforementioned pool have been well-represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
  • 1.1.2 Expanding Applications in NIPT Products
• 1.2 Supply Chain Overview
• 1.3 Research and Development Review
  • 1.3.1 Patent Filing Trend (by Country, Year)
• 1.4 Regulatory Landscape
  • 1.4.1 Regulatory Scenario in the U.S.
  • 1.4.2 Regulatory Scenario in Canada
  • 1.4.3 Regulatory Scenario in the U.K.
  • 1.4.4 Regulatory Scenario in Germany
  • 1.4.5 Regulatory Scenario in France
  • 1.4.6 Regulatory Scenario in Spain
  • 1.4.7 Regulatory Scenario in Italy
  • 1.4.8 Regulatory Scenario in the Netherlands
  • 1.4.9 Regulatory Scenario in China
  • 1.4.10 Regulatory Scenario in India
  • 1.4.11 Regulatory Scenario in Australia
  • 1.4.12 Regulatory Scenario in Japan
• 1.5 Reimbursement Scenario
• 1.6 Market Dynamics Overview
  • 1.6.1 Market Drivers
    • 1.6.1.1 High Incidence of Genetic Disorders
    • 1.6.1.2 Rising Maternal Age
    • 1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
    • 1.6.1.4 Increased Emphasis on Early Detection and Prevention
  • 1.6.2 Market Restraints
    • 1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
    • 1.6.2.2 Lack of Awareness Regarding NIPT
    • 1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
  • 1.6.3 Market Opportunities
    • 1.6.3.1 Leveraging the Opportunities Arising from the Growing Markets in Asia
    • 1.6.3.2 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)

2 Application

• 2.1 Application Segmentation
• 2.2 Application Summary
  • 2.2.1 Application Summary
  • 2.2.2 End User Summary
• 2.3 Global Non-Invasive Prenatal Testing Market (by Application)
  • 2.3.1 Trisomy Detection
  • 2.3.2 Microdeletion Detection
  • 2.3.3 Sex Chromosome Aneuploidy Detection
  • 2.3.4 Others
• 2.4 Global Non-Invasive Prenatal Testing Market (by End User)
  • 2.4.1 Hospital
  • 2.4.2 Clinics
  • 2.4.3 Diagnostic Labs
  • 2.4.4 Others

3 Products

• 3.1 Product Segmentation
• 3.2 Product Summary
  • 3.2.1 Test Summary
  • 3.2.2 Platform Summary
  • 3.2.3 Method Summary
• 3.3 Global Non-Invasive Prenatal Testing Market (by Test)
  • 3.3.1 Panorama and Vistara
  • 3.3.2 MaterniT GENOME, MaterniT21 PLUS, and informaSeq
  • 3.3.3 Verifi and Verifi Plus Prenatal Tests
  • 3.3.4 NIFTY Test and NIFTY-Test Oro
  • 3.3.5 QNatal Advanced
  • 3.3.6 PrenaTest, GenaSafe, and PrenatalSAFE
  • 3.3.7 Bambini Test
  • 3.3.8 IONA and Sage
  • 3.3.9 Other Harmony Test
• 3.4 Global Non-Invasive Prenatal Testing Market (by Method)
  • 3.4.1 cfDNA
  • 3.4.2 FCMB
• 3.5 Global Non-Invasive Prenatal Testing Market (by Platform)
  • 3.5.1 NGS
  • 3.5.2 PCR
  • 3.5.3 Others

4 Regions

• 4.1 Drivers and Restraints
• 4.2 Regional Summary
• 4.3 North America
  • 4.3.1 Regional Overview
  • 4.3.2 Driving Factors for Market Growth
  • 4.3.3 Factors Challenging the Market
  • 4.3.4 Application
  • 4.3.5 Product
  • 4.3.6 U.S.
  • 4.3.7 Canada
• 4.4 Europe
  • 4.4.1 Regional Overview
  • 4.4.2 Driving Factors for Market Growth
  • 4.4.3 Factors Challenging the Market
  • 4.4.4 Application
  • 4.4.5 Product
  • 4.4.6 France
  • 4.4.7 Germany
  • 4.4.8 U.K.
  • 4.4.9 Spain
  • 4.4.10 Italy
  • 4.4.11 Rest-of-Europe
• 4.5 Asia-Pacific
  • 4.5.1 Regional Overview
  • 4.5.2 Driving Factors for Market Growth
  • 4.5.3 Factors Challenging the Market
  • 4.5.4 Application
  • 4.5.5 Product
  • 4.5.6 China
  • 4.5.7 India
  • 4.5.8 Japan
  • 4.5.9 Rest-of-Asia-Pacific
• 4.6 Latin America
  • 4.6.1 Regional Overview
  • 4.6.2 Driving Factors for Market Growth
  • 4.6.3 Factors Challenging the Market
  • 4.6.4 Application
  • 4.6.5 Product
  • 4.6.6 Brazil
  • 4.6.7 Mexico
  • 4.6.8 Rest-of-Latin America
• 4.7 Middle East and Africa
  • 4.7.1 Regional Overview
  • 4.7.2 Driving Factors for Market Growth
  • 4.7.3 Factors Challenging the Market
  • 4.7.4 Application
  • 4.7.5 Product
  • 4.7.6 U.A.E.
  • 4.7.7 South Africa
  • 4.7.8 Rest-of-Middle East and Africa

5 Markets - Competitive Benchmarking & Company Profiles

• 5.1 Next Frontiers
• 5.2 Competitive Landscape
  • 5.2.1 Agilent Technologies, Inc.
    • 5.2.1.1 Overview
    • 5.2.1.2 Product Portfolio
    • 5.2.1.3 Top Competitors
    • 5.2.1.4 Key Personnel
    • 5.2.1.5 Target Customers
    • 5.2.1.6 Analyst View
  • 5.2.2 F. Hoffmann-La Roche Ltd
    • 5.2.2.1 Overview
    • 5.2.2.2 Product Portfolio
    • 5.2.2.3 Top Competitors
    • 5.2.2.4 Target Customers
    • 5.2.2.5 Key Personnel
    • 5.2.2.6 Analyst View
  • 5.2.3 PerkinElmer, Inc.
    • 5.2.3.1 Overview
    • 5.2.3.2 Product Portfolio
    • 5.2.3.3 Top Competitors
    • 5.2.3.4 Target Customers
    • 5.2.3.5 Key Personnel
    • 5.2.3.6 Analyst View
  • 5.2.4 Quest Diagnostics Incorporated
    • 5.2.4.1 Overview
    • 5.2.4.2 Product Portfolio
    • 5.2.4.3 Top Competitors
    • 5.2.4.4 Target Customers
    • 5.2.4.5 Key Personnel
    • 5.2.4.6 Analyst View
  • 5.2.5 Illumina, Inc.
    • 5.2.5.1 Overview
    • 5.2.5.2 Product Portfolio
    • 5.2.5.3 Top Competitors
    • 5.2.5.4 Target Customers
    • 5.2.5.5 Key Personnel
    • 5.2.5.6 Analyst View
  • 5.2.6 Myriad Genetics, Inc.
    • 5.2.6.1 Overview
    • 5.2.6.2 Product Portfolio
    • 5.2.6.3 Top Competitors
    • 5.2.6.4 Target Customers
    • 5.2.6.5 Key Personnel
    • 5.2.6.6 Analyst View
  • 5.2.7 BGI Genomics
    • 5.2.7.1 Overview
    • 5.2.7.2 Product Portfolio
    • 5.2.7.3 Top Competitors
    • 5.2.7.4 Target Customers
    • 5.2.7.5 Key Personnel
    • 5.2.7.6 Analyst View
  • 5.2.8 CENTOGENE N.V.
    • 5.2.8.1 Overview
    • 5.2.8.2 Product Portfolio
    • 5.2.8.3 Top Competitors
    • 5.2.8.4 Target Customers
    • 5.2.8.5 Key Personnel
    • 5.2.8.6 Analyst View
  • 5.2.9 Laboratory Corporation of America Holdings
    • 5.2.9.1 Overview
    • 5.2.9.2 Product Portfolio
    • 5.2.9.3 Top Competitors
    • 5.2.9.4 Target Customers
    • 5.2.9.5 Key Personnel
    • 5.2.9.6 Analyst View
  • 5.2.10 MedGenome Inc.
    • 5.2.10.1 Overview
    • 5.2.10.2 Product Portfolio
    • 5.2.10.3 Top Competitors
    • 5.2.10.4 Target Customers
    • 5.2.10.5 Key Personnel
    • 5.2.10.6 Analyst View
  • 5.2.11 Annoroad Gene Technology
    • 5.2.11.1 Overview
    • 5.2.11.2 Product Portfolio
    • 5.2.11.3 Top Competitors
    • 5.2.11.4 Target Customers
    • 5.2.11.5 Key Personnel
    • 5.2.11.6 Analyst View
  • 5.2.1 Natera, Inc.
    • 5.2.1.1 Overview
    • 5.2.1.2 Product Portfolio
    • 5.2.1.3 Top Competitors
    • 5.2.1.4 Target Customers
    • 5.2.1.5 Key Personnel
    • 5.2.1.6 Analyst View
  • 5.2.2 Yourgene Health
    • 5.2.2.1 Overview
    • 5.2.2.2 Product Portfolio
    • 5.2.2.3 Top Competitors
    • 5.2.2.4 Target Customers
    • 5.2.2.5 Key Personnel
    • 5.2.2.6 Analyst View
  • 5.2.3 Eurofins Scientific SE
    • 5.2.3.1 Overview
    • 5.2.3.2 Product Portfolio
    • 5.2.3.3 Top Competitors
    • 5.2.3.4 Target Customers
    • 5.2.3.5 Key Personnel
    • 5.2.3.6 Analyst View
  • 5.2.4 Next Biosciences
    • 5.2.4.1 Overview
    • 5.2.4.2 Product Portfolio
    • 5.2.4.3 Top Competitors
    • 5.2.4.4 Target Customers
    • 5.2.4.5 Key Personnel
    • 5.2.4.6 Analyst View

6 Research Methodology

• 6.1 Data Sources
  • 6.1.1 Primary Data Sources
  • 6.1.2 Secondary Data Sources
  • 6.1.3 Data Triangulation
• 6.2 Market Estimation and Forecast